Huma-Folacid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Huma-Folacid

Overview of Huma-Folacid

Huma-Folacid is a therapeutic preparation containing folic acid, a synthetic form of folate, which is a water-soluble B-vitamin (Vitamin B9). This compound is essential for several critical biological processes, including the synthesis of nucleic acids and the maintenance of normal red blood cell production.

Mechanism of Action

Folic acid acts as a precursor to tetrahydrofolate, a coenzyme involved in carbon transfer reactions. These reactions are fundamental to the following physiological functions:

  • DNA Synthesis and Repair: Folic acid is required for the formation and maintenance of new cells, particularly during periods of rapid cell division.
  • Amino Acid Metabolism: It plays a role in the conversion of homocysteine to methionine, an essential amino acid used in protein synthesis.
  • Erythropoiesis: It supports the maturation of red blood cells in the bone marrow.

Clinical Applications

Huma-Folacid is primarily utilized to address folate deficiency and its associated physiological consequences. Folate deficiency can arise from various factors, such as inadequate dietary intake, malabsorption syndromes, or increased physiological demand.

Key areas where Huma-Folacid is applied include:

  • Management of Folate Deficiency Anemia: It is used to treat megaloblastic anemia, a condition characterized by the production of abnormally large and dysfunctional red blood cells due to a lack of folate.
  • Support During Increased Demand: The preparation may be used in situations where the body requires higher levels of folate to support metabolic processes.
  • Prophylaxis: It is used as a preventive measure in populations at risk of developing a deficiency to ensure the maintenance of healthy folate levels in the blood and tissues.

What side effects are possible with Huma-Folacid?

Possible Side Effects and Safety Information

The safety profile for Huma-Folacid (Folic Acid) is primarily established by regulatory authorities based on its low incidence of adverse effects and specific restrictions regarding use in certain patient groups.

Officially Documented Side Effects

Adverse reactions associated with this medicine are generally rare and mainly involve the immune system and skin. These reactions are classified in regulatory documents under System-Organ Classes such as Immune System Disorders and Skin and Subcutaneous Tissue Disorders.

Adverse Reaction Category Frequency Classification
Hypersensitivity Reactions Rare
Anaphylactic Shock Very Rare
Skin Reactions (e.g., pruritus, erythema, urticaria) Uncommon to Rare

Hypersensitivity reactions may manifest as skin symptoms, and in very rare cases, a severe, systemic reaction known as anaphylactic shock may occur.

Safety-Related Restrictions and Cautions

The medicine is subject to specific regulatory limitations to ensure safety:

  • Contraindication: Huma-Folacid is strictly contraindicated for patients with a complete deficiency of the enzyme Dihydropyrimidine Dehydrogenase (DPD). This restriction is critical because use in DPD-deficient patients may lead to severe, life-threatening toxicity observed with related substances.

  • Masking of Deficiency: Official safety notes indicate that this medicine may mask the hematological signs of an underlying Vitamin B12 deficiency while allowing the associated neurological damage to progress unnoticed. Therefore, a regulatory caution exists regarding its use when Vitamin B12 deficiency has not been excluded or treated.

Population-Specific Use

Regulatory documentation generally supports the established safety of Folic Acid for use in women of childbearing potential, during pregnancy, and in infancy, when administered for its authorized indications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Folic Acid (Huma-Folacid) classifies the active substance as relatively nontoxic in humans. Consequently, no specific antidote is known or listed in regulatory documentation for overdose management.


Documented Overdose Manifestations

Symptoms reported in regulatory labeling are typically associated with the chronic ingestion of very high doses (e.g., 15 mg daily for one month) and include reversible effects on the gastrointestinal and nervous systems:

  • Gastrointestinal Effects: Loss of appetite (anorexia), a bitter or bad taste, abdominal distension, and flatulence.
  • Central Nervous System (CNS) Effects: Altered sleep patterns, difficulty concentrating, irritability, excitement, mental depression, and confusion.

Mandated Emergency Actions

Regulatory authorities explicitly mandate that immediate medical help must be sought in the event of suspected overdose or a severe reaction:

  • Seek immediate medical attention by calling a doctor or Poison Control Center (or emergency services) in case of accidental overdose.
  • Urgent help is required for signs of a severe allergic reaction, such as swelling of the face, tongue, or throat, or difficulty breathing (bronchospasm).

Specific Overdose Considerations

High-dose Folic Acid exposure carries a specific, regulator-documented risk of increasing the incidence or intensity of epileptic attacks in patients simultaneously taking certain antiepileptic medications. Furthermore, regulatory labels warn that doses exceeding 0.1 mg daily may obscure the diagnosis of pernicious anemia by allowing neurological damage to progress.

Therapeutic Uses of Huma-Folacid

Huma-Folacid (Folic Acid) is commonly used across therapeutic domains addressing nutritional deficits relevant to blood health and fetal development. The key benefit is providing essential physiological support to help manage symptoms of deficiency and contribute to lowering the risk of developmental issues. This medicine is primarily used to help manage three major therapeutic areas.

The primary indications include being used for managing or lowering the risk of folate deficiency anemia (specifically the megaloblastic or macrocytic types); providing essential preventative support related to Neural Tube Defects (NTDs) during the early periconceptional period; and acting as a supportive agent alongside certain anti-inflammatory treatments. This medicine is applied in situations where deficiency leads to symptom clusters that create noticeable physiological strain, such as extreme fatigue, headaches, and mucosal irritation like a sore, red tongue.

“This essential preventative use supports the fetus during the key phase of nervous system development.”


Quick Facts on Therapeutic Use

Focus Area Primary Benefit
Deficiency Symptoms Helps ease the overall symptom burden of fatigue and weakness.
Periconceptional Period Contributes to lowering the risk of major congenital developmental issues.
Supportive Care Used for managing secondary symptoms intensified by certain chronic treatments.

Eligibility and Restrictions for Use

Who can and cannot use Huma-Folacid?

This section defines the official eligibility for Folic Acid (Huma-Folacid) based strictly on governmental regulatory labeling, detailing who is allowed to use the medicine and who is prohibited.


Populations for Whom Use is Contraindicated

Huma-Folacid must not be used by patients with untreated cobalamin (Vitamin B12) deficiency, as use could mask the condition. It is also strictly contraindicated for individuals with a known hypersensitivity to Folic Acid or any of the product's excipients. Regulatory guidance restricts use in patients with malignant disease, unless the megaloblastic anemia is conclusively due to folate deficiency.


Eligibility Across Life Stages and Conditions

Use is generally allowed for adults, including the elderly, and for children over one year of age. The medicine is specifically permitted and documented for use by women planning pregnancy, throughout pregnancy, and during lactation. Eligibility is also established for patients with chronic conditions requiring prophylaxis, such as renal dialysis or chronic haemolytic states.


Use Restrictions

Conditional use warnings apply when treating undiagnosed megaloblastic anaemia to prevent misdiagnosis. Older adults on long-term therapy may require specific testing to confirm continued eligibility. Certain tablet formulations are contraindicated for patients with rare hereditary sugar intolerance (e.g., galactose malabsorption) due to non-active ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Huma-Folacid (Folic Acid) is primarily structured by its potential to interact with agents that disrupt folate metabolism or by its own effect on the efficacy of co-administered medicines.

Documented Pharmacodynamic and Efficacy Interactions

  • Antiepileptic Drugs: Folic Acid in large amounts may officially antagonize the anticonvulsant effect of medicines such as Phenytoin, Phenobarbital, and Primidone, potentially reducing their therapeutic efficacy.
  • Folate Antagonists: Co-administration with agents that actively interfere with folate metabolism, including Methotrexate, Pyrimethamine, and Trimethoprim, may lead to or intensify a state of folate deficiency.

Interactions Affecting Folic Acid Exposure

Certain substances can reduce the body's ability to absorb Folic Acid, thus lowering its exposure. Medicines such as Sulfasalazine and certain Antacids (those containing aluminum or magnesium) are documented to interfere with Folic Acid absorption.

Administration of Folic Acid must be separated from antacids containing aluminum or magnesium by at least 2 hours to prevent this reduction in absorption.

Interactions with Other Substances and Conditions

The regulatory label notes that chronic alcohol consumption can lead to folate deficiency, requiring potential consideration for increased Folic Acid maintenance levels in that population. Furthermore, Folic Acid is documented to potentially reduce the effectiveness of Zinc supplements.

Restriction: The administration of Folic Acid alone is designated as improper therapy in cases of undiagnosed megaloblastic anemia where a Vitamin B12 deficiency is the underlying cause. This is due to the risk of masking the deficiency's hematologic signs while allowing neurological manifestations to progress.

Mechanism of Action

Essential Cofactor for DNA and Methylation

Huma-Folacid (Folic Acid) functions as a precursor that is reduced by the enzyme Dihydrofolate Reductase (DHFR) into its active co-factor form, Tetrahydrofolate (THF). THF derivatives enter the one-carbon metabolic cycle, where they fulfill two primary roles.

First, THF derivatives donate one-carbon units necessary for the synthesis of purine and thymidylate nucleotides, a reaction catalyzed by Thymidylate Synthase (TS). This molecular cascade directly influences DNA and RNA synthesis and supports the proliferation and maturation of rapidly dividing cells, particularly in the bone marrow (hematopoiesis).

Second, the active derivative 5-methyl THF serves as a crucial methyl donor for the enzyme Methionine Synthase, which facilitates the conversion of the amino acid homocysteine back into methionine. This enzymatic action regulates the plasma concentration of homocysteine. The drug is also involved in processes that influence the function of the system regulating blood vessel tone.

Dosage and Administration Information

How to Use Huma-Folacid

This section describes the high-level, standardized usage principles for Huma-Folacid (Folic Acid).


Administration and Dosing Principles

The medicine is most frequently administered orally as a tablet and can be taken with or without food. The parenteral (intramuscular, intravenous, or subcutaneous) route is reserved for individuals with severe intestinal malabsorption or when oral intake is compromised.

For the treatment of folate deficiency anemia, the usual adult daily therapeutic dose ranges from 0.25 mg to 1.0 mg. This phase is typically followed by a long-term maintenance dose of approximately 0.4 mg daily. When used for high-risk prophylaxis, such as the prevention of neural tube defects, the prescribed dose is generally 4 mg to 5 mg daily.

Frequency and Course Duration

Administration is typically once daily for both therapeutic and prophylactic regimens. The course for correcting established deficiency anemia is commonly set at four months to ensure blood normalization, after which a patient transitions to the maintenance level. For preventative use in the periconceptional period, the 4 mg or 5 mg dose must begin before conception and continue throughout the first trimester of pregnancy.


Procedural Administration Constraints

Constraint Instruction Summary
Timing with other drugs Must be separated by 4 to 6 hours from bile acid sequestrants (e.g., cholestyramine) to ensure proper absorption.
Dose Limitation Daily doses exceeding 0.1 mg must not be administered unless co-existing Vitamin B12 deficiency has been ruled out or is being concurrently managed.
Missed Dose If a dose is missed, patients should skip the missed dose and resume the next scheduled dose; doubling the dose is not supported by label instructions.

Recent Clinical Evidence

Research evidence / Overview of studies for Huma-Folacid


Evidence for use in Anemia (Folate Deficiency)

Research has explored the use of Huma-Folacid in individuals who have low folate levels, which may be a contributing factor to certain types of anemia. Studies was evaluated in settings involving nutritional or malabsorption-related folate deficiency. The findings describe patterns observed in the studies where individuals receiving Huma-Folacid had changes outcomes related to systemic or functional imbalance, specifically in blood measures that reflect the body's folate status and the production of red blood cells.

Evidence for use during Pregnancy (Neural Tube Defect Prevention)

Huma-Folacid was studied for its potential role in relation to the risk of neural tube defects (NTDs) in the children of women who are planning or are in the early stages of pregnancy. Research in this area examined outcomes in populations where symptoms may vary in intensity. Studies describe the patterns of NTD occurrence in groups using Huma-Folacid compared to those using other forms of folate or a placebo. The certainty around the findings remains low for some subgroups, and data for certain groups remain insufficient.

Evidence for use in Conditions related to High Homocysteine Levels

The relationship between Huma-Folacid and blood levels of homocysteine was studied for individuals presenting with elevated levels of this amino acid. Research explored the use of Huma-Folacid as part of trials that was evaluated in individuals with certain conditions characterized by fluctuating or episodic manifestations. The data show patterns related to changes in homocysteine levels that was associated with the use of Huma-Folacid in some observed populations. Findings were mixed across some studies, and certainty remains low about the long-term implications of these changes.


Long-term studies and follow-up

Research was studied for its ability to provide insight into the effects of Huma-Folacid over extended periods. Currently, follow-up durations were limited in many of the key trials. This means there is limited information for long-term outcomes regarding how studies report how symptoms evolved in the observed populations over many years. The evidence is still emerging regarding very long-term safety and sustained outcomes reflecting daily functioning or activity level.

What is still uncertain about Huma-Folacid

The research contributes to understanding symptom patterns and physiological changes, but several aspects may still be unclear. One uncertainty is the full range of observed changes across diverse populations, as evidence quality varies across studies and comparative evidence is lacking against all relevant alternatives. The evidence highlights what is known — and what is still uncertain, and research is ongoing to address these gaps and further contextualize the findings.

Key Studies & References

  1. Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
  2. Folic Acid Deficiency (StatPearls - NCBI Bookshelf - NIH)
  3. Comparative Study between the Use of Regular Folic Acid Supplement versus the Use of L-Methyl Folate in Patients with Methyl Tetrahydrofolate Reductase (MTHFR) Gene Mutation with Recurrent Pregnancy Loss
  4. Label: L-METHYLFOLATE CALCIUM- levomefolate calcium tablet, coated (DailyMed/FDA)

Frequently Asked Questions (FAQ)

Common questions about Huma-Folacid (FAQ)

Q: Is Huma-Folacid considered a medication or a supplement?

A: Huma-Folacid is classified as a medicinal preparation. According to official regulatory systems, it belongs to the pharmacological class of Anti-anemia preparations. While its active ingredient is a B-complex vitamin, its regulatory classification and use for treating or preventing specific deficiencies confirm its status as a licensed medicine.

Q: Are there any long-term effects of taking Huma-Folacid?

A: Official research reviews indicate that information regarding the effects of Huma-Folacid over very long periods is limited. This is because the follow-up periods in many of the key trials were constrained. Evidence is still emerging concerning sustained long-term outcomes for individuals using the medicine for many years.

Q: Is Huma-Folacid safe to take if I have kidney issues?

A: Official guidance on eligibility notes that the medicine is permitted for use in individuals with chronic conditions like renal dialysis. For other, non-dialysis-related kidney issues, the regulatory label generally does not list a specific contraindication or special warning.

Q: Does Huma-Folacid interact with caffeine or alcohol?

A: The regulatory label notes that chronic alcohol consumption can lead to folate deficiency, which may need to be considered by the prescribing professional. However, caffeine is not typically listed as a specific substance known to interact with Huma-Folacid.

Q: Why is Huma-Folacid not recommended for people with certain types of anemia?

A: The medicine is restricted when the type of megaloblastic anemia has not been fully diagnosed. This caution exists because Huma-Folacid may hide the blood-related signs of a Vitamin B12 deficiency. Allowing the deficiency to remain untreated carries a risk that associated neurological damage could progress without being noticed.

Q: What does the FDA (or equivalent) label say about Huma-Folacid's effectiveness?

A: Official documentation describes the medicine’s effectiveness in relation to its intended physiological role. This includes its role in supporting the synthesis of healthy cells and addressing low folate levels. The outcomes reported in studies reflect changes in blood measures related to the body's folate status and red blood cell production.

Q: Is Huma-Folacid generally well-tolerated?

A: Official product information indicates that adverse reactions associated with Huma-Folacid are rare. The documented side effects mainly involve the immune system and the skin, suggesting that the medicine is typically well-tolerated by most patients.

Q: Do I need to adjust my diet while taking Huma-Folacid?

A: The medicine's administration instructions state it can be taken with or without food. Beyond this, regulatory documents do not list specific foods that must be avoided. The only substance noted in relation to long-term folate status is chronic alcohol consumption.

Q: Does Huma-Folacid have any known impact on hair loss or skin conditions?

A: Official documentation classifies certain side effects under Skin and Subcutaneous Tissue Disorders. These include reactions like pruritus (itching), erythema, and urticaria (hives). However, hair loss is generally not listed among the officially documented adverse reactions.

Q: Is Huma-Folacid suitable for individuals who are lactose intolerant?

A: The suitability of Huma-Folacid for individuals with lactose intolerance is dependent on the inactive ingredients in the specific formulation. Regulatory documents caution that certain tablet types are contraindicated for patients with a rare hereditary sugar intolerance.

Q: Why do doctors prescribe Huma-Folacid instead of standard vitamins?

A: Regulatory documents indicate that the medicine is prescribed for situations where the synthetic form is necessary to achieve a specific therapeutic goal. This is intended to provide predictable therapeutic outcomes and the ability to administer the precise dosing required to correct or prevent a deficiency.

Q: How quickly should I expect to notice any difference after starting Huma-Folacid?

A: The time frame for observing physiological changes varies based on the purpose of use. For established deficiency anemia, the therapeutic course is commonly set at approximately four months with the goal of normalizing blood measures, indicating that results are measured over this period.

Q: Is it normal to feel slightly nauseous when first starting Huma-Folacid?

A: Nausea is not typically listed among the officially documented, commonly reported adverse effects. Official documents classify adverse reactions as rare, mainly involving the immune system and the skin.

Q: Can Huma-Folacid affect my sleep patterns?

A: Official safety information does not typically list disturbances to sleep patterns or insomnia among the known side effects. Adverse reactions are generally rare and minor.

Q: Can Huma-Folacid interact with my blood pressure medicine?

A: The interaction profile focuses on agents that interfere with folate metabolism, such as certain antiepileptic drugs and folate antagonists. Regulatory documents generally do not contain a specific warning regarding interactions with common blood pressure medications (antihypertensives).

Q: Are there specific foods I should avoid while using Huma-Folacid?

A: Official documentation does not list specific foods that must be avoided while using this medicine. The administration instructions state that it can be taken with or without food.

Q: What research has been done on Huma-Folacid for nerve health?

A: Official research reviews primarily detail findings related to anemia, neural tube defects, and homocysteine levels. Although a safety caution exists regarding the potential for neurological damage in cases of unmanaged Vitamin B12 deficiency, research explicitly targeting 'nerve health' as a primary indication is not typically summarized in regulatory overviews.

Q: Can Huma-Folacid be crushed or mixed into food/drinks?

A: Official administration instructions define the standard routes (oral tablet, injection solution). The physical manipulation of the tablet, such as crushing or mixing it into food, is generally not addressed in official labeling. When specific instructions are absent from the official labeling, the tablet is typically intended to be administered in its whole form.

Q: Does taking Huma-Folacid affect the results of any common blood tests?

A: Regulatory documents note its intended effect on certain hematological signs (blood measures) as part of its therapeutic goal in anemia. However, the product information does not typically list interferences with common blood chemistry or coagulation tests.

Q: Is Huma-Folacid safe for people with a history of heart problems?

A: According to official regulatory documents, there is no specific contraindication or special warning listed regarding the use of Huma-Folacid for patients with a history of heart problems.

Q: What happens if I accidentally take more Huma-Folacid than prescribed?

A: Official documents generally indicate that Folic Acid has a wide therapeutic index, meaning large doses are typically well tolerated. Should more than the prescribed amount be taken, the recommended treatment is usually symptomatic support, as a specific antidote is not required.

Q: Is it okay to take Huma-Folacid if I am also taking a multivitamin?

A: The official interaction profile lists specific warnings for agents that interfere with folate metabolism or absorption, such as Zinc supplements. However, the regulatory documents do not provide general guidance on combining Huma-Folacid with a multivitamin containing numerous ingredients.

Q: What is the difference between Huma-Folacid and L-methylfolate?

A: Huma-Folacid is the synthetic inactive precursor known as Folic Acid. This form must be processed by the body's enzymes to become the active form. L-methylfolate (or 5-methyl-THF) is the active, methylated form of the vitamin that the body directly utilizes.

Q: Does Huma-Folacid cause weight gain or loss?

A: Weight gain or loss is not listed among the officially documented side effects found in the regulatory documents for Huma-Folacid.

Q: Are there any known sexual side effects from Huma-Folacid?

A: Sexual side effects are not listed among the officially documented adverse reactions in the regulatory documents for Huma-Folacid.

Q: Does Huma-Folacid interact with herbal supplements like St. John's Wort?

A: The regulatory interaction profile mainly focuses on prescription and over-the-counter medicines, along with specific substances like alcohol and zinc. There is no specific warning listed in official documents regarding St. John’s Wort or generalized herbal supplements.

Q: Can Huma-Folacid cause anxiety or changes in mood?

A: Anxiety or changes in mood are not typically listed among the officially documented side effects reported for Huma-Folacid.

Q: Can I drive or operate machinery while taking Huma-Folacid?

A: Official regulatory labels generally state that Folic Acid has no or negligible influence on a person’s ability to drive or operate machinery.

Q: Does Huma-Folacid affect fertility?

A: Official documents generally state that Folic Acid has no known adverse effects on fertility when the medicine is used at the recommended therapeutic doses.

Q: Are there known interactions with over-the-counter pain relievers and Huma-Folacid?

A: The interaction profile focuses on agents that disrupt the body's folate metabolism. Regulatory documents generally do not contain a specific warning regarding common over-the-counter pain relievers like NSAIDs or acetaminophen.

Q: Why is the active ingredient in Huma-Folacid considered 'activated'?

A: The active ingredient, Folic Acid, is a synthetic inactive precursor that requires processing by the body's enzymes to become usable. It must be reduced into its active co-factor form, Tetrahydrofolate, which is the substance commonly referred to as the 'activated' vitamin.

Q: Can people with diabetes safely use Huma-Folacid?

A: There is no specific contraindication or special warning regarding the use of Folic Acid for patients with diabetes listed in the regulatory documents.

How should Huma-Folacid be stored and disposed of?

Storage and Disposal of Huma-Folacid (Folic Acid)


Official Storage Conditions

Huma-Folacid (Folic Acid) must be stored at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F). The product must be protected from excessive heat, light, and moisture. Due to stability concerns, especially for solutions, official labeling requires protection from light and heat, as the substance can decompose rapidly.

Packaging and Safety Rules

The container for oral formulations must be kept tightly closed. For injection solutions, vials must be retained in the carton until use. All forms of the medicine must be stored out of the reach of children, aligning with mandatory safety requirements.

Disposal

Unused or expired Huma-Folacid must be disposed of in accordance with local and national regulations for pharmaceutical waste, as directed by official regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Huma-Folacid found in:

A-Z Index: